Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00010
|
|||||
| Drug Name |
Enalapril
|
|||||
| Synonyms |
(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid; Enalapril (INN); Enalapril (TN); N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; Renitec (TN); Vasotec; Vasotec (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11:BA00] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H28N2O5
|
|||||
| Canonical SMILES |
CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O
|
|||||
| InChI |
InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
|
|||||
| InChIKey |
GBXSMTUPTTWBMN-XIRDDKMYSA-N
|
|||||
| CAS Number |
CAS 75847-73-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 376.4 | Topological Polar Surface Area | 95.9 | ||
| Heavy Atom Count | 27 | Rotatable Bond Count | 10 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
-0.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103179319
,103928457
,11112847
,11335583
,11360822
,11364201
,11366763
,11369325
,11372634
,11373494
,11377487
,113955320
,11461794
,11485085
,11489271
,11491293
,11491823
,11495121
,127931871
,134358398
,135012773
,137100856
,140098266
,14779899
,14877707
,17185069
,29214998
,39404326
,46507920
,47365119
,47588933
,47588934
,47810682
,48110391
,48184936
,48415941
,49698433
,50073899
,50103938
,50103939
,53787340
,57362754
,75931775
,7979157
,89736144
,9191
,92309084
,93166909
,96024588
,99313640
|
|||||
| ChEBI ID |
ChEBI:4784
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [3] | ||
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [4] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [2] | ||
| PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [5] | ||
| PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [6] | ||
| References | ||||||
| 1 | Enalapril was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402. | |||||
| 3 | Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6. | |||||
| 4 | The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6. | |||||
| 5 | The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60. | |||||
| 6 | Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.